Skip to main content
SpringerLink
Log in

Clinical Translation in Central Nervous System Diseases: Ethical and Social Challenges

  • Reference work entry
  • First Online:
Handbook of Neuroethics

Abstract

The entire trajectory of neurological research is rife with uncertainty and risk. Despite the abundance of new molecular targets, therapeutic platforms, and increasingly sophisticated theories of pathophysiology, drug development in neurology remains a failure-prone endeavor. This risk, and its reciprocal opportunity, is thick with ethical and epistemic challenges. Given the low likelihood of demonstrating clinical utility and the devastating impact of neurological disease, what neurological interventions should be investigated? What level of evidence provides a warrant for exposing nonhuman animals and human beings to burdensome and often invasive strategies? This chapter examines some of the ethical and social dimensions of translating new neurological interventions from laboratory concept into various stages of clinical development, focusing on the dominant ethical and epistemic issues as they emerge (and reemerge) throughout the knowledge production process. It concludes with a brief discussion of several relatively uncharted ethical and epistemic questions as they pertain to CNS clinical translation.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 999.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 999.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Bath, P. M., Macleod, M. R., & Green, A. R. (2009). Emulating multicentre clinical stroke trials: A new paradigm for studying novel interventions in experimental models of stroke. International Journal of Stroke, 4, 471–479.

    Article  Google Scholar 

  • Begley, C. G., & Ellis, L. M. (2012). Drug development: Raise standards for preclinical cancer research. Nature, 483, 531–533.

    Article  Google Scholar 

  • Belmont Report. (1979). The Belmont report: Ethical principles and guidelines for the protection of human subjects of research. hhs.gov/ohrp/humansubjects/guidance/belmont.html. Retrieved 15 Jan 2013.

  • Braude, P., Minger, S. L., & Warwick, R. M. (2005). Stem cell therapy: Hope or hype? British Medical Journal, 330, 1159–1160.

    Article  Google Scholar 

  • Brazzelli, M., Lewis, S. C., Deeks, J. J., & Sandercock, P. A. (2009). No evidence of bias in the process of publication of diagnostic accuracy studies in stroke submitted as abstracts. Journal of Clinical Epidemiology, 62, 425–430.

    Article  Google Scholar 

  • Brott, T. G., Hobson, R. W., Jr., Howard, G., Roubin, G. S., Clark, W. M., Brooks, W., Mackey, A., Hill, M. D., Leimgruber, P. P., Sheffet, A. J., Howard, V. J., Moore, W. S., Voeks, J. H., Hopkins, L. N., Cutlip, D. E., Cohen, D. J., Popma, J. J., Ferguson, R. D., Cohen, S. N., Blackshear, J. L., Silver, F. L., Mohr, J. P., Lal, B. K., Meschia, J. F., & CREST Investigators. (2010). Stenting versus endarterectomy for treatment of carotid-artery stenosis. The New England Journal of Medicine, 363, 11–23.

    Article  Google Scholar 

  • Committee on the Use of Chimpanzees in Biomedical and Behavioral Research, National Research Council. (2011). In B. M. Altevogt, D. E. Pankevich, M. K. Shelton-Davenport, & J. P. Kahn (Eds.), Chimpanzees in biomedical research: Assessing the necessity. Washington, DC: The National Academy Press.

    Google Scholar 

  • Cudkowicz, M. E., Shefner, J. M., Schoenfeld, D. A., Brown, R. H., Jr., Johnson, H., Qureshi, M., Jacobs, M., Rothstein, J. D., Appel, S. H., Pascuzzi, R. M., Heiman-Patterson, T. D., Donofrio, P. D., David, W. S., Russell, J. A., Tandan, R., Pioro, E. P., Felice, K. J., Rosenfeld, J., Mandler, R. N., Sachs, G. M., Bradley, W. G., Raynor, E. M., Baquis, G. D., Belsh, J. M., Novella, S., Goldstein, J., Hulihan, J., & Northeast ALS Consortium. (2003). A randomized, placebo-controlled trial of topiramate in amyotrophic lateral sclerosis. Neurology, 61, 456–464.

    Article  Google Scholar 

  • Cudkowicz, M. E., Shefner, J. M., Schoenfeld, D. A., Zhang, H., Andreasson, K. I., Rothstein, J. D., & Drachman, D. B. (2006). Trial of celecoxib in amyotrophic lateral sclerosis. Annals of Neurology, 60, 22–31.

    Article  Google Scholar 

  • de la Fuente-Fernández, R., Schulzer, M., & Stoessl, A. J. (2002). The placebo effect in neurological disorders. Lancet Neurology, 1, 85–91.

    Article  Google Scholar 

  • Degrazia, D. (1999). The ethics of animal research: What are the prospects for agreement? Cambridge Quarterly of Healthcare Ethics, 8, 23–34.

    Article  Google Scholar 

  • Duggan, P. S., Siegel, A. W., Blass, D. M., Bok, H., Coyle, J. T., Faden, R., Finkel, J., Gearhart, J. D., Greely, H. T., Hillis, A., Hoke, A., Johnson, R., Johnston, M., Kahn, J., Kerr, D., King, P., Kurtzberg, J., Liao, S. M., McDonald, J. W., McKhann, G., Nelson, K. B., Rao, M., Regenberg, A., Smith, K., Solter, D., Song, H., Sugarman, J., Traystman, R. J., Vescovi, A., Yanofski, J., Young, W., & Mathews, D. J. (2009). Unintended changes in cognition, mood, and behavior arising from cell-based interventions for neurological conditions: Ethical challenges. The American Journal of Bioethics, 9, 31–36.

    Article  Google Scholar 

  • Eichler, H., Pignatti, F., Flamion, B., Leufkens, H., & Breckenridge, A. (2008). Balancing early market access to new drugs with the need for benefit/risk data: A mounting dilemma. Nature Reviews. Drug Discovery, 7, 818–826.

    Article  Google Scholar 

  • Fisher, M., Feuerstein, G., Howells, D. W., Hurn, P. D., Kent, T. A., et al. (2009). Update of the stroke therapy academic industry roundtable preclinical recommendations. Stroke, 40, 2244–2250.

    Article  Google Scholar 

  • Freedman, B. (1987). Equipoise and the ethics of clinical research. The New England Journal of Medicine, 317, 141–145.

    Article  Google Scholar 

  • Greene, M., Schill, K., Takahashi, S., Bateman-House, A., Beauchamp, T., Bok, H., Cheney, D., Coyle, J., Deacon, T., Dennett, D., Donovan, P., Flanagan, O., Goldman, S., Greely, H., Martin, L., Miller, E., Mueller, D., Siegel, A., Solter, D., Gearhart, J., McKhann, G., & Faden, R. (2005). Moral issues of human-non-human primate neural grafting. Science, 309, 385–386.

    Article  Google Scholar 

  • Henderson, V., Kimmelman, J., Fergusson, D., Grimshaw, J., & Hackam, D. (2013). Threats to validity in the design and conduct of preclinical efficacy studies: A systematic review of guidelines for in vivo animal experiments. PLoS Medicine, 10, e1001489.

    Google Scholar 

  • Hey, S. P., & Kimmelman, J. (n.d.). Ethics, error, and initial trials of efficacy. Science Translational Medicine, (accepted).

    Google Scholar 

  • Jonas, H. (1969). Philosophical reflections on experimenting with human subject. Daedalus, 98, 219–247.

    Google Scholar 

  • Karlawish, J. H. T. (2003). Research involving cognitively impaired adults. The New England Journal of Medicine, 348, 1389–1392.

    Article  Google Scholar 

  • Kilkenny, C., Browne, W. J., Cuthill, I. C., Emerson, M., & Altman, D. G. (2010). Improving bioscience research reporting: The ARRIVE guidelines for reporting animal research. PLoS Biology, 8, e1000412.

    Article  Google Scholar 

  • Kim, S. Y. H., Schrock, L., Wilson, R. M., Frank, S. A., Holloway, R. G., Kieburtz, K., & de Vries, R. G. (2009). An approach to evaluating the therapeutic misconception. IRB, 31, 7–14.

    Google Scholar 

  • Kimmelman, J. (2009). Gene transfer and ethics of first-in-human experiments: Lost in translation. New York: Cambridge University Press.

    Book  Google Scholar 

  • Kimmelman, J. (2012). A theoretical framework for early human studies: Uncertainty, intervention ensembles, and boundaries. Trials, 13, 173 [Epub ahead of print].

    Article  Google Scholar 

  • Kimmelman, J., & Anderson, J. (2012). Should preclinical studies be registered? Nature Biotechnology, 30, 488–489.

    Article  Google Scholar 

  • Kimmelman, J., & London, A. J. (2011). Predicting harms and benefits in translational trials: Ethics, evidence, and uncertainty. PLoS Medicine, 8, e1001010.

    Article  Google Scholar 

  • Kimmelman, J., Duckworth, K., Ramsay, T., Voss, T., Ravina, B., & Emborg, M. E. (2011). Risk of surgical delivery to deep nuclei: A meta-analysis. Movement Disorders, 26, 1415–1421.

    Article  Google Scholar 

  • Kola, I., & Landis, J. (2004). Can the pharmaceutical industry reduce attrition rates? Nature Reviews. Drug Discovery, 3, 711–715.

    Article  Google Scholar 

  • Lafollette, H., & Shanks, N. (1996). Brute science: Dilemmas of animal experimentation. London: Routledge.

    Google Scholar 

  • Lang, A. E., Gill, S., Patel, N. K., Lozano, A., Nutt, J. G., Penn, R., Brooks, D. J., Hotton, G., Moro, E., Heywood, P., Brodsky, M. A., Burchiel, K., Kelly, P., Dalvi, A., Scott, B., Stacy, M., Turner, D., Wooten, V. G., Elias, W. J., Laws, E. R., Dhawan, V., Stoessl, A. J., Matcham, J., Coffey, R. J., & Traub, M. (2006). Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. Annals of Neurology, 59, 711–715.

    Article  Google Scholar 

  • Ledford, H. (2010). Key Alzheimer’s findings questioned. Nature, 466, 1031.

    Article  Google Scholar 

  • Liebeskind, D. S., Kidwell, C. S., Sayre, J. W., & Saver, J. L. (2006). Evidence of publication bias in reporting acute stroke clinical trials. Neurology, 67, 973–979.

    Article  Google Scholar 

  • London, A. J., Kimmelman, J., & Carlisle, B. (2012). Rethinking research ethics: The case of postmarketing trials. Science, 336, 544–545.

    Article  Google Scholar 

  • Lowenstein, P. R. (2008). A call for physiopathological ethics. Molecular Therapy, 16, 1771–1772.

    Article  Google Scholar 

  • Ludolph, A. C., Bendotti, C., Blaugrund, E., Chio, A., Greensmith, L., et al. (2010). Guidelines for preclinical animal research in ALS/MND: A consensus meeting. Amyotrophic Lateral Sclerosis, 11, 38–45.

    Article  Google Scholar 

  • Mullard, A. (2011). Reliability of ‘new drug target’ claims called into question. Nature Reviews. Drug Discovery, 10, 643–644.

    Article  Google Scholar 

  • Pangaloss, M. N., Schechter, L. E., & Hurko, O. (2007). Drug development for CNS disorders: Strategies for balancing risk and reducing attrition. Nature Reviews. Drug Discovery, 6, 521–532.

    Article  Google Scholar 

  • Perel, P., Roberts, I., Sena, E., Philipa, W., Briscoe, C., Sandercock, P., Macleod, M., Mignini, L. E., Jayaram, P., & Khan, K. S. (2007). Comparison of treatment effects between animal experiments and clinical trials: Systematic review. British Medical Journal, 334, 197–200.

    Article  Google Scholar 

  • Pocock, S. (1979). Allocation of patients to treatment in clinical trials. Biometrics, 35, 183–197.

    Article  Google Scholar 

  • Polman, C. H., Reingold, S. C., Barkhof, F., Calabresi, P. A., Clanet, M., Cohen, J. A., Cutter, G. R., Freedman, M. S., Kappos, L., Lublin, F. D., McFarland, H. F., Metz, L. M., Miller, A. E., Montalban, X., O’Connor, P. W., Panitch, H., Richert, J. R., Petkau, J., Schwid, S. R., Sormani, M. P., Thompson, A. J., Weinshenker, B. G., & Wolinsky, J. S. (2008). Ethics of placebo-controlled clinical trials in multiple sclerosis: A reassessment. Neurology, 70, 1134–1140.

    Article  Google Scholar 

  • Psaty, B. M., & Kronmal, R. A. (2008). Reporting mortality findings in trials of rofecoxib for Alzheimer disease or cognitive impairment: A case study based on documents from rofecoxib litigation. Journal of the American Medical Association, 299, 1813–1817.

    Article  Google Scholar 

  • Ringach, D. L. (2011). The use of nonhuman animals in biomedical research. The American Journal of the Medical Sciences, 342, 305–313.

    Article  Google Scholar 

  • Sandercock, P., & Roberts, I. (2002). Systematic reviews of animal experiments. The Lancet, 360, 586.

    Article  Google Scholar 

  • Sanossian, N., Ohanian, A. G., Saver, J. L., Kim, L. I., & Ovbiagele, B. (2006). Frequency and determinants of nonpublication of research in the stroke literature. Stroke, 37, 2588–2592.

    Article  Google Scholar 

  • Schott, S., & James, S. D. (2012). Case study: IViG keeps alzheimer’s at bay for a decade. ABC News Web, July 19.

    Google Scholar 

  • Sena, E. S., van der Worp, H. B., Bath, P. M., Howells, D. W., & Macleod, M. R. (2010). Publication bias in reports of animal stroke studies leads to major overstatement of efficacy. PLoS Biology, 8, e1000344.

    Article  Google Scholar 

  • Singer, P. (1990). Animal liberation (2nd ed.). New York: New York Review.

    Google Scholar 

  • Streiffer, R. (2005). At the edge of humanity: Human stem cells, chimeras, and moral status. Kennedy Institute of Ethics Journal, 15, 347–370.

    Article  Google Scholar 

  • Stroke Therapy Academic Industry Recommendations (STAIR). (1999). Recommendations for standards regarding preclinical neuroprotective and restorative drug development. Stroke, 30, 2752–2758.

    Article  Google Scholar 

  • Sughrue, M. E., Mocco, J., Mack, W. J., Ducruet, A. F., Komotar, R. J., Fischbach, R. L., Martin, T. E., & Connolly, E. S. (2009). Bioethical considerations in translational research: Primate stroke. The American Journal of Bioethics, 9, 3–12.

    Article  Google Scholar 

  • Sulmasy, D. P., Astrow, A. B., He, M. K., Seils, D. M., Meropol, N. J., Micco, E., & Weinfurt, K. P. (2010). The culture of faith and hope: Patients’ justifications for their high estimations of expected therapeutic benefit when enrolling in early phase oncology trials. Cancer, 116, 3702–3711.

    Article  Google Scholar 

  • US Department of Health and Human Services (DHHS). (2009). Protection of human subjects. 45 CFR 46.

    Google Scholar 

  • US Food, and Drug Administration (US FDA). (2006). Guidance for Industry. INDS – Approaches to Complying with CGMP During Phase 1(Draft Guidance). US Department of Health and Human Services.

    Google Scholar 

  • van der Worp, H. B., de Haan, P., Morrema, E., & Kalkman, C. J. (2005). Methodological quality of animal studies on neuroprotection in focal cerebral ischaemia. Journal of Neurology, 252, 1108–1114.

    Article  Google Scholar 

  • van der Worp, H. B., Howells, D. W., Sena, E. S., Porritt, M. J., Rewell, S., O’Collins, V., & Macleod, M. R. (2010). Can animal models of disease reliably inform human studies? PLoS Medicine, 7, e1000245.

    Article  Google Scholar 

  • Vedula, S. S., Bero, L., Scherer, R. W., & Dickersin, K. (2009). Outcome reporting in industry-sponsored trials of gabapentin for off-label use. The New England Journal of Medicine, 361, 1963–1971.

    Article  Google Scholar 

  • Vedula, S. S., Goldman, P. S., Rona, I. J., Greene, T. M., & Dickersin, K. (2012). Implementation of a publication strategy in the context of reporting biases. A case study based on new documents from neurontin litigation. Trials, 13, 136.

    Article  Google Scholar 

  • Vickrey, B. G., Hirtz, D., Waddy, S., Cheng, E. M., & Johnston, S. C. (2012). Comparative effectiveness and implementation research: Directions for neurology. Annals of Neurology, 71, 732–742.

    Article  Google Scholar 

  • Wadman, M. (2011). Animal rights: Chimpanzee research on trial. Nature, 474, 268–271.

    Article  Google Scholar 

  • Weatherall, D. (2006). The use of non-human primates in research: a working group report chaired by Sir David Weatherall. The Academy of Medical Sciences [online].

    Google Scholar 

  • Weijer, C., & Miller, P. B. (2004). When are research risks reasonable in relation to anticipated benefits? Nature, 10, 570–573.

    Google Scholar 

  • Weijer, C., Shapiro, S. H., & Glass, K. C. (2000). Clinical equipoise and not the uncertainty principle is the moral underpinning of the randomised controlled trial. British Medical Journal, 321, 756–758.

    Article  Google Scholar 

  • Weinfurt, K. P., Seils, D. M., Tzeng, J. P., Compton, K. L., Sulmasy, D. P., Astrow, A. B., Solarino, N. A., Schulman, K. A., & Meropol, N. J. (2008). Expectations of benefit in early-phase clinical trials: Implications for assessing the adequacy of informed consent. Medical Decision Making, 28, 575–581.

    Article  Google Scholar 

  • Wheble, P. C., Sena, E. S., & Macleod, M. R. (2008). A systematic review and meta-analysis of the efficacy of piracetam and piracetam-like compounds in experimental stroke. Cerebrovascular Diseases, 25, 5–11.

    Article  Google Scholar 

  • World Health Organization (WHO). (2006). Neurological disorders: Public health challenges. Geneva: World Health Organization.

    Google Scholar 

  • World Medical Association (WMA). (2011). WMA Declaration of Helsinki: Ethical principles for medical research involving human subjects. www.wma.net/en/30publications/10policies/b3

  • Zamboni, P., Galeotti, R., Weinstock-Guttman, B., Kennedy, C., Salvi, F., & Zivadinov, R. (2012). Venous angioplasty in patients with multiple sclerosis: Results of a pilot study. European Journal of Vascular and Endovascular Surgery, 43, 116–122.

    Article  Google Scholar 

  • Ziring, P. R., Brazdziunas, D., Cooley, W. C., Kastner, T. A., Kummer, M. E., Gonzalez de Pijem, L., Quint, R. D., Ruppert, E. S., & Sandler, A. D. (1999). American Academy of Pediatrics. Committee on Children with Disabilities. The treatment of neurologically impaired children using patterning. Pediatrics, 104, 1149–1151.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Studies for Translation, Ethics and Medicine (STREAM), Biomedical Ethics/Social Studies of Medicine/Department of Human Genetics, McGill University, 3647 Peel Street, Montreal, QC, H3A 1X1, Canada

    Jonathan Kimmelman

  2. Biomedical Ethics Unit, McGill University, 3647 Peel Street, Montreal, QC, H3A 1X1, Canada

    Spencer Phillips Hey

Authors
  1. Jonathan Kimmelman
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Spencer Phillips Hey
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jonathan Kimmelman .

Editor information

Editors and Affiliations

  1. Institute for Ethics and History of Medicine, University of Tübingen, Tübingen, Germany

    Jens Clausen

  2. The Florey Institute of Neuroscience and Mental Health, University of Melbourne, Parkville, Australia

    Neil Levy

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer Science+Business Media Dordrecht

About this entry

Cite this entry

Kimmelman, J., Hey, S.P. (2015). Clinical Translation in Central Nervous System Diseases: Ethical and Social Challenges. In: Clausen, J., Levy, N. (eds) Handbook of Neuroethics. Springer, Dordrecht. https://doi.org/10.1007/978-94-007-4707-4_130

Download citation

  • DOI: https://doi.org/10.1007/978-94-007-4707-4_130

  • Published:

  • Publisher Name: Springer, Dordrecht

  • Print ISBN: 978-94-007-4706-7

  • Online ISBN: 978-94-007-4707-4

  • eBook Packages: Humanities, Social Sciences and Law

Publish with us

Policies and ethics

Search

Navigation